Columna Capital agreed to acquire Evidenze Group to expand CRO services across Europe, adding a trials contractor with operations across Spain, Germany, Italy, and Portugal plus a partner network in additional countries. The deal is positioned as a growth accelerator, with Evidenze serving more than 270 clients and maintaining a technology and data capabilities focus. The transaction follows Evidenze’s prior acquisition of Antares Consulting and comes amid steady European clinical trial investment growth. For sponsors, expanded CRO footprints can translate into more capacity for multi-country studies and potentially tighter operational execution. Columna’s move reflects ongoing consolidation in clinical services, where analytics, trial execution infrastructure, and geographic coverage increasingly determine which CROs win and retain major pharma and biotech accounts.